American Patients vs Foreign Governments — A Tale of 2 Value Sets Read more about American Patients vs Foreign Governments — A Tale of 2 Value Sets
NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Read more about NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program
Assessing Commercial Health Plan Responsiveness to FDA Label Changes Read more about Assessing Commercial Health Plan Responsiveness to FDA Label Changes
Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program Read more about Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program
Generic Entry and the Early Impact on U.S. Pharmaceutical Spending Read more about Generic Entry and the Early Impact on U.S. Pharmaceutical Spending
Unmet Need in the IRA Drug Price Negotiation Program Read more about Unmet Need in the IRA Drug Price Negotiation Program
Does Delaying Coverage for Accelerated Approval Treatments Disproportionately Impact Patients With High Unmet Needs? Read more about Does Delaying Coverage for Accelerated Approval Treatments Disproportionately Impact Patients With High Unmet Needs?
Geographic Disparities in Influenza Vaccination Among Medicaid Beneficiaries: A National Analysis Read more about Geographic Disparities in Influenza Vaccination Among Medicaid Beneficiaries: A National Analysis
Maximum Fair Price Effectuation and Independent Pharmacies: Risks to Patient Access and Choice Read more about Maximum Fair Price Effectuation and Independent Pharmacies: Risks to Patient Access and Choice
New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives Read more about New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives